iShares Select Dividend ETF (DVY)
- Previous Close
120.92 - Open
120.13 - Bid 119.78 x 200
- Ask 120.07 x 200
- Day's Range
119.21 - 120.82 - 52 Week Range
102.66 - 123.43 - Volume
194,681 - Avg. Volume
549,279 - Net Assets 19B
- NAV 120.92
- PE Ratio (TTM) 13.11
- Yield 3.62%
- YTD Daily Total Return 4.01%
- Beta (5Y Monthly) 0.74
- Expense Ratio (net) 0.38%
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index measures the performance of the U.S.'s leading stocks by dividend yield.
iShares
Fund Family
Large Value
Fund Category
19B
Net Assets
2003-11-03
Inception Date
Performance Overview: DVY
Trailing returns as of 4/24/2024. Category is Large Value.
People Also Watch
Holdings: DVY
Top 10 Holdings (18.19% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: DVY
Technical Assessment: Neutral in the Intermediate-Term
While the major indices paused Wednesday in advance of important quarterly reports from mega Technology names, we will look at the technical condition of the largest holdings in the Nasdaq 100 (QQQ). Of note, after the close, META reported and is down over13% ahead of the open today.
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetO: What does Argus have to say about O?
REALTY INCOME CORP has an Investment Rating of SELL; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetAnalyst Report: Realty Income Corporation
Realty Income owns roughly 13,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, gaming, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
RatingPrice Target